Division of Hematology/Medical Oncology, Knight Cancer Institute, Portland, Oregon.
Department of Pediatrics, Oregon Health & Science University, Portland, Oregon.
Am J Hematol. 2017 Feb;92(2):204-208. doi: 10.1002/ajh.24593.
Clinicians, including hematologists, are more frequently encountering transgender individuals in practice; however, most lack training on the management and complications of transgender medicine. Hormonal therapy forms the backbone of medical interventions for patients undergoing gender transition. While supplementing an individual's intrinsic sex hormone is associated with a variety of hematologic complications including increased rates of venous thrombosis, cardiovascular events, erthyrocytosis, and malignancy, the risks of supplementing with opposing sex hormones are not well understood. Data on the hematologic complications of these therapies are accumulating but remain limited, and clinicians have little experience with their management. This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence-based management going forward. Am. J. Hematol. 92:204-208, 2017. © 2016 Wiley Periodicals, Inc.
临床医生，包括血液科医生，在实践中越来越多地遇到跨性别者；然而，大多数人缺乏关于跨性别医学的管理和并发症的培训。激素治疗是患者进行性别转换的医学干预的基础。虽然补充个体的内源性性激素与多种血液学并发症相关，包括静脉血栓形成、心血管事件、红细胞增多症和恶性肿瘤的发生率增加，但补充相反性别激素的风险尚不清楚。关于这些治疗方法的血液学并发症的数据正在积累，但仍然有限，临床医生在管理这些并发症方面经验有限。这篇综述强调了目前在跨性别医学中可用的干预措施以及相关的潜在血液学并发症，并提出了简单的、基于证据的管理方法。美国血液学杂志 92：204-208，2017。©2016 年威利父子公司
